Business development, licensing, and corporate strategy
Open a company and see what it has approved, what is active, what it dropped, what it has raised and which patent and regulatory dates are coming. Figures link to the filing or registry entry they came from.
Individual plan, $249/seat/mo. Card required.
A first-pass screen means the trial registry for the pipeline, SEC filings for the money, patent listings for the timing and a spreadsheet to hold them together. The same asset appears under a code name in one source and a brand name in another, so the competitor count is never quite right. By the time the picture is assembled, the conversation has moved on.
Pages marked free open without an account. The rest open in the product, starting with a 14-day trial.
A biomarker page labels each piece of evidence by type, so you can see whether the biomarker behind an asset has an FDA companion diagnostic assertion or only a target-disease association. The BRAF page shows how one gene's evidence splits across the types. The BRAF page lists 19 FDA companion diagnostic assertions today.
Free to read Biomarkers Open the BRAF page
Each company page sorts its programs into In development, Approved and Abandoned, drawn from public trial and approval records. The financial lens on the same page carries the figures the company reported to the SEC.
In the product: Companies
A target page charts the programs aimed at it by phase and names the drugs acting on it and the companies developing against it, which shows who a licensed asset would compete with. It also lists discontinued programs, and it labels its crowding counts as a floor on the field and not the whole of it.
In the product: Targets
Funding lists private placements and public offerings drawn from SEC filings, with NIH grants and SBIR/STTR awards alongside. Each round has its own page with its date, round type and issuer. Where the filing states an offering size, the page shows it, and where a source filing is on record it links to it on SEC EDGAR.
In the product: Funding
The Calendar puts a target's next FDA decision on a dated list, with the drug and sponsor attached where the match holds up, so regulatory timing can be set against the deal timeline. The dates are extracted from public SEC 8-K and 6-K filings, and the Individual plan adds the licensed Benzinga catalyst calendar, shown with its attribution.
In the product: Calendar
Patent Cliff lists drugs still under patent protection by the year that protection lapses, so the entry window for a licensing target is a dated chart, with the drugs that already have a biosimilar available marked. Exposure is sized by the revenue a company discloses for the drug and, where none is disclosed, by US Medicare spend.
In the product: Patent Cliff
Patent Cliff sizes exposure by the revenue a company discloses for a drug and, where none is disclosed, by US Medicare spend, a US public-payer measure. Funding shows what companies have disclosed publicly, so a private raise that was never filed will not appear.
Every answer above marked "In the product" opens with the Individual plan.
Individual plan, $249/seat/mo, card required.
